Anaplastic Large Cell Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Relapsed/refractory ALCL patients have many treatment options. For primary cutaneous ALCL the following treatments have been approved by the U.S. Food and Drug Administration (FDA):
- Brentuximab vedotin (Adcetris)
For systemic ALCL the following treatments have been approved by the U.S. Food and Drug Administration (FDA) :
- Romidepsin (Istodax)
- Belinostat (Beleodaq)
- Pralatrexate (Folotyn)
- Brentuximab vedotin (Adcetris)
Learn More
To learn more about ALCL, download the Anaplastic Large Cell Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.
Additional Resources
To learn more about ALCL, download the Anaplastic Large Cell Lymphoma Fact Sheet.
Events
-
Lymphoma Talk: Minneapolis
Minneapolis Marriott City Center 30 South 7th Street, Minneapolis, MinnesotaLymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides information about lymphoma in three breakout sessions.
-
Living with Lymphoma
Virtual EventLiving with Lymphoma provides the latest information about lymphoma diagnosis, current treatment options, and patient support issues.
-
What Care Partners Should Know Webinar
Virtual EventWebinars are hour-long interactive programs discussing the diagnosis and treatment of specific lymphoma subtypes and key research and treatment updates. Webinars feature a presentation from the featured expert, with the remainder of the time allocated to an extensive Q&A session. Program Overview: